Description

(3R,5R)-5-[2-[2-[2-(3-Methoxyphenyl)Ethyl]Phenoxy]Ethyl]-1-Methyl-3-Pyrrolidinol Hydrochloride is a high-purity, single-enantiomer pharmaceutical intermediate of significant commercial importance. This compound is valued for its role as a critical building block in the synthesis of advanced active pharmaceutical ingredients (APIs), particularly in cardiovascular and metabolic therapeutic areas. It is essential for research institutions, contract development and manufacturing organizations (CDMOs), and pharmaceutical companies engaged in the development of novel chiral drugs.

Application

• Pharmaceutical Intermediate: A key chiral synthon in the multi-step synthesis of complex drug molecules, especially statins and related compounds.
• Active Pharmaceutical Ingredient (API) Development: Serves as a core structural component for new chemical entities (NCEs) targeting HMG-CoA reductase inhibition.
• Process Chemistry & Scale-Up: Used in route scouting, optimization, and pilot-scale manufacturing for clinical trial material supply.
• Biochemical Research: Employed in enzymatic and receptor-binding studies to investigate mechanisms of action related to cholesterol biosynthesis.
• Reference Standard: Sourced for analytical method development, validation, and quality control testing in GMP environments.
• Asymmetric Synthesis: Utilized in chiral pool synthesis to introduce defined stereochemistry into more complex molecular architectures.

Basic Information

Product Name	(3R,5R)-5-[2-[2-[2-(3-Methoxyphenyl)Ethyl]Phenoxy]Ethyl]-1-Methyl-3-Pyrrolidinol Hydrochloride
CAS No.	167144-79-8
Molecular Formula	C24H33NO3 • HCl
Molecular Weight	424.0 g/mol (approx.)
Synonyms	(3R,5R)-Atorvastatin Intermediate; (3R,5R)-5-(4-Fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl]-2-isopropyl-1H-pyrrole-3-carboxylic Acid Related Compound; (3R-cis)-1,2,3,5-Tetrahydro-2-oxo-5-(phenylmethyl)-4H-pyrrolo[1,2-a][1,4]benzodiazepine-4-carboxamide Derivative; (3R,5R)-Fluvastatin Intermediate; 1-Methyl-3-pyrrolidinol, 5-[2-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]ethyl]-, hydrochloride, (3R,5R)-; (3R,5R)-5-(2-(2-(2-(3-Methoxyphenyl)ethyl)phenoxy)ethyl)-1-methylpyrrolidin-3-ol hydrochloride
EINECS	Contact for details

Quality Control

Our production of this chiral intermediate adheres to strict quality management systems, ensuring batch-to-batch consistency for critical pharmaceutical applications. Quality is verified through comprehensive analytical testing, including chiral HPLC to confirm enantiomeric excess (ee) and standard pharmacopeial methods. A Certificate of Analysis (COA) detailing identity, purity, assay, and impurity profile is provided with each shipment. We support development under GMP-like conditions and can tailor specifications to meet the rigorous requirements of clinical phase manufacturing.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed in a dry environment to prevent moisture absorption, which can affect stability and handling properties. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Enantiomeric Excess (Chiral HPLC)	≥ 99.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm
Related Substances (HPLC)	Total impurities ≤ 2.0%; Any single impurity ≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.